Filtered By:
Cancer: Breast Cancer
This page shows you your search results in order of date. This is page number 17.
Order by Relevance | Date
Total 60669 results found since Jan 2013.
Incorporating Value-Based Decisions in Breast Cancer Treatment Algorithms
Surg Oncol Clin N Am. 2023 Oct;32(4):777-797. doi: 10.1016/j.soc.2023.05.008. Epub 2023 Jun 9.ABSTRACTGiven the excellent prognosis and availability of evidence-based treatment, patients with early-stage breast cancer are at risk of overtreatment. In this review, we summarize key opportunities to incorporate value-based decisions to optimize the delivery of high-value treatment across the breast cancer care continuum.PMID:37714643 | DOI:10.1016/j.soc.2023.05.008
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Ton Wang Lesly A Dossett Source Type: research
Fertility and Sexual Health in Young Women with Early-Stage Breast Cancer
Surg Oncol Clin N Am. 2023 Oct;32(4):747-759. doi: 10.1016/j.soc.2023.05.012. Epub 2023 Jun 15.ABSTRACTFertility and sexual health may be impaired by early breast cancer treatment in young women, and these issues should be addressed at diagnosis and through survivorship. Future fertility interest and risk should be considered and communicated, and early referral made to an infertility specialist for those interested. Data regarding safety of fertility preservation options as well as pregnancy after breast cancer are overall reassuring. Patients should be counseled about the impact of systemic therapies and breast surgeries...
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Marla Lipsyc-Sharf Ann H Partridge Source Type: research
Selecting Triple Negative Breast Cancer Patients for Immunotherapy
Surg Oncol Clin N Am. 2023 Oct;32(4):733-745. doi: 10.1016/j.soc.2023.05.005. Epub 2023 Jun 5.ABSTRACTThe approval of preoperative immunotherapy combined with chemotherapy is a practice-changing advance for patients with early-stage triple-negative breast cancer. The optimal patient selection requires careful attention to staging and balancing potential risks with expected benefits, particularly as it relates to immune-related adverse events.PMID:37714640 | DOI:10.1016/j.soc.2023.05.005
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Stephanie Downs-Canner Elizabeth A Mittendorf Source Type: research
Incorporating Tumor Biology to Select Patients for the Omission of Radiation Therapy
Surg Oncol Clin N Am. 2023 Oct;32(4):725-732. doi: 10.1016/j.soc.2023.05.006. Epub 2023 Jun 9.ABSTRACTAlthough adjuvant breast radiotherapy has long been a universal component of breast conservation therapy (BCT), it is now clear that "breast cancer" is a broad class of many disparate diseases with varying natural histories and risk profiles. In turn, some breast conservation patients enjoy exceedingly favorable outcomes following surgery alone. Ongoing trials seek to identify such low-risk patient populations, hypothesizing that some may safely forego radiotherapy. Whereas prior-generation trials focused on clinicopatholo...
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Lior Z Braunstein Source Type: research
Managing the Morbidity: Individualizing Risk Assessment, Diagnosis, and Treatment Options for Upper Extremity Lymphedema
Surg Oncol Clin N Am. 2023 Oct;32(4):705-724. doi: 10.1016/j.soc.2023.05.004. Epub 2023 Jun 25.ABSTRACTIn the setting where breast cancer-related lymphedema (BCRL) remains a feared and common complication of breast cancer, here we review important factors for the development, diagnosis, prevention, and treatment of BCRL. We find that race/ethnicity affect BCRL development risk, that future studies should focus on understanding the biological reasons behind the increased susceptibility of certain racial minorities to BCRL, that surveillance, early detection, exercise programs, and arm compression can reduce the risk of BCRL...
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Giacomo Montagna Andrea V Barrio Source Type: research
Is Axillary Staging Obsolete in Early Breast Cancer?
This article reviews the incidence of nodal metastases in early-stage breast cancer and the need for axillary staging to maintain local control in the axilla or to determine the need for adjuvant systemic therapy across the spectrum of patients with breast cancer, and reviews clinical trials addressing this question. At present, sentinel lymph node biopsy should be omitted in women age ≥70 years with cT1-2 N0, HR+/HER2- cancers. The importance of nodal status in selecting patients for radiotherapy remains the main reason for axillary staging in younger postmenopausal women with cT1-2N0, HR+/HER2- cancers.PMID:37714636 | ...
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Monica Morrow Source Type: research
How to Navigate the Treatment Spectrum from Multimodality Therapy to Observation Alone for ductal carcinoma in situ
Surg Oncol Clin N Am. 2023 Oct;32(4):663-673. doi: 10.1016/j.soc.2023.05.011. Epub 2023 Jun 15.ABSTRACTDCIS detection has increased dramatically since the introduction of screening mammography. Current guidance concordant care recommends surgical intervention for all patients with DCIS, followed by radiation and/or endocrine therapy for some. Adjuvant therapies after surgical excision have reduced recurrence rates but not breast cancer mortality. Given the lack of evidence of current treatment regimens and the morbidity associated with these treatments, there is concern that DCIS is over-treated. Active surveillance may be...
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Sydney M Record Eun-Sil Shelley Hwang Akiko Chiba Source Type: research
Individualizing Breast Cancer Risk Assessment in Clinical Practice
Surg Oncol Clin N Am. 2023 Oct;32(4):647-661. doi: 10.1016/j.soc.2023.05.013. Epub 2023 Jul 6.ABSTRACTMultiple tools exist to assess a patient's breast cancer risk. The choice of risk model depends on the patient's risk factors and how the calculation will impact care. High-risk patients-those with a lifetime breast cancer risk of ≥20%-are, for instance, eligible for supplemental screening with breast magnetic resonance imaging. Those with an elevated short-term breast cancer risk (frequently defined as a 5-year risk ≥1.66%) should be offered endocrine prophylaxis. High-risk patients should also receive guidance on mod...
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Amy E Cyr Kaitlyn Kennard Source Type: research
Breast Cancer Risk Reduction: Current Status and Emerging Trends to Increase Efficacy and Reduce Toxicity of Preventive Medication
Surg Oncol Clin N Am. 2023 Oct;32(4):631-646. doi: 10.1016/j.soc.2023.05.001. Epub 2023 Jun 15.ABSTRACTThe primary prevention of breast cancer is a worthwhile goal for which the efficacy of antiestrogens is well established. However, implementation has been problematic related to low prioritization by providers and the reluctance of high-risk women to experience medication side effects. Emerging solutions include improved risk estimation through the use of polygenic risk scores and the application of radiomics to screening mammograms; and optimization of medication dose to limit toxicity. The identification of agents to pr...
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Seema Ahsan Khan Source Type: research
Prognostic model of ER-positive, HER2-negative breast cancer predicted by clinically relevant indicators
CONCLUSION: To generate nomograms that predicted DFS and OS, independent predictors of DFS in ER-positive/HER2-negative breast cancer patients were chosen. The nomograms successfully stratified patients into prognostic categories and worked well in both internal validation and external validation.PMID:37713046 | DOI:10.1007/s12094-023-03316-0
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Xinming Song Pintian Wang Ruiling Feng Mandika Chetry E Li Xiaohua Wu Zewa Liu Shasha Liao Jing Lin Source Type: research
Machine learning- and WGCNA-mediated double analysis based on genes associated with disulfidptosis, cuproptosis and ferroptosis for the construction and validation of the prognostic model for breast cancer
CONCLUSION: Multiplex analysis based on DRGs, CRGs and FRGs correlated strongly with BC, providing new insights for developing clinical prognostic tools and designing immunotherapy regimens for BC patients.PMID:37712959 | DOI:10.1007/s00432-023-05378-7
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Lijun Xu Shanshan Wang Dan Zhang Yunxi Wu Jiali Shan Huixia Zhu Chongyu Wang Qingqing Wang Source Type: research
The value of radiomics model based on ultrasound image features in the differentiation between minimal breast cancer and small benign breast masses
CONCLUSION: The radiomics model based on ultrasound image features has a satisfied predictive ability for small breast masses, and is expected to become a potential tool for the diagnosis of MBC, and it is a zero cost (in terms of patient participation and imaging time).PMID:37712556 | DOI:10.1002/jcu.23556
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Shuyi Lyu Meiwu Zhang Baisong Zhang Jiazhen Zhu Libo Gao Yuqin Qiu Liu Yang Yan Zhang Source Type: research
Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response
J Clin Invest. 2023 Sep 15;133(18):e172156. doi: 10.1172/JCI172156.ABSTRACTAntibody-drug conjugates (ADCs) have emerged as a revolutionary therapeutic class, combining the precise targeting ability of monoclonal antibodies with the potent cytotoxic effects of chemotherapeutics. Notably, ADCs have rapidly advanced in the field of breast cancer treatment. This innovative approach holds promise for strengthening the immune system through antibody-mediated cellular toxicity, tumor-specific immunity, and adaptive immune responses. However, the development of upfront and acquired resistance poses substantial challenges in maximi...
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Hannah L Chang Blake Schwettmann Heather L McArthur Isaac S Chan Source Type: research
Meta-analysis of integrated ChIP-seq and transcriptome data revealed genomic regions affected by estrogen receptor alpha in breast cancer
CONCLUSION: The meta-analysis of ChIP-seq data of estrogen-treated MCF7 cell line leads to the identification of new binding sites of ER that have not been previously reported. Also, enrichment of the meta-differentially bound sites and their associated genes revealed new terms and pathways involved in the development of breast cancer which should be examined in future in vitro and in vivo studies.PMID:37715225 | DOI:10.1186/s12920-023-01655-z
Source: Cancer Control - September 15, 2023 Category: Cancer & Oncology Authors: Zeynab Piryaei Zahra Salehi Esmaeil Ebrahimie Mansour Ebrahimi Kaveh Kavousi Source Type: research
Value of Echocardiography and Cardiac Magnetic resonance in assessing left ventricular function in breast and gastric cancer patients after Anthracycline Chemotherapy
CONCLUSION: Breast and gastric cancer patients exhibited elevated levels of hs-cTnT after 6 cycles of chemotherapy, indicating potential cardiotoxicity. Additionally, cardiac MRI and 2-dimensional ECHO showed good agreement in assessing left ventricular function, with ECHO tending to underestimate volume measurements compared to MRI.PMID:37715125 | PMC:PMC10504696 | DOI:10.1186/s12872-023-03495-2
Source: Cancer Control - September 15, 2023 Category: Cancer & Oncology Authors: Chao-Long Jin Xue-Gong Shi Ting-Ting Wang Hong-Wen Li Ding-Xin Zhang Zhe Sheng Jie Xiao Yong-Qiang Yu Source Type: research
